Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

INGR1D is a large screening study in the Thames Valley to identify infants who are at risk of developing type 1 diabetes.

INGR1D is a large screening study in the Thames Valley to identify infants who are at risk of developing type 1 diabetes. The test is available as part of a research study being carried out by staff of the NHS and the University of Oxford. GPPAD

 INGR1D








INGR1D Study in the Thames Valley

ABOUT THE STUDY  

In the first week of life, newborns are checked for treatable metabolic and hormonal disorders as part of the standard newborn screening tests. We would like to let you know about the option of another free screening test to identify children at high risk of developing type 1 diabetes. The test is available as part of a research study being carried out by staff of the NHS and the University of Oxford. This extra test can be performed on blood that has already been collected. There are no extra needles or blood tests required for this diabetes screening and taking part is voluntary. For further information, please read our study leaflet. 

Type 1 diabetes is a common metabolic disease in children and adolescents caused by insulin deficiency. The deficiency is due to a faulty immune system. The body’s own defence system attacks insulin-producing cells in the pancreas and destroys them. As a result, children with type 1 diabetes require life-long treatment with insulin. One difficult aspect of type 1 diabetes is that it is usually only recognised when the person affected already has serious and sometimes even life-threatening symptoms.

Type 1 diabetes primarily occurs in individuals who have certain high risk genes. Most children who have these high risk genes and develop diabetes do not have any relatives with diabetes. In other words, the disease can affect anyone.

If your child is found to have genes giving an increased risk for diabetes, we will contact you and advise you on the results as well as inviting your child to take part in a prevention study, POInT (Primary Oral Insulin Trial). The aim of the POInT study is to find ways to prevent the disease.

If you would you like to learn more about the risk of type 1 diabetes or preventive treatment visit our FAQ's or contact us using the details below.

Contact details:

The INGR1D Study Team

Nuffield Department of Women’s and Reproductive Health, University of Oxford

The Women’s Centre, John Radcliffe Hospital

Oxford

OX3 9DU

Phone: 01865 572258

Email: INGR1D@wrh.ox.ac.uk

Website: www.ingr1d.org.uk

WHO CAN PARTICIPATE IN THIS STUDY? 

Any pregnant woman in the Thames Valley can participate.

Women will be approached in the Ultrasound Dept. of their local hospital when they are due to have a scan, or after their baby is born and before the new born screening test is carried out.

Women who are interested can contact the Research Midwife at their local hospital.

ETHICAL APPROVAL 

This study has been ethically approved by the Hampshire A Ethics Committee.

Ref number 18/SC/0005

Matthew Snape 

BRC Consultant in General Paediatrics and VaccinologyMatthew Snape

                                                                             

Related research themes